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Abstract Survivin is one of the inhibitors of apoptosis
proteins (IAP) that might play an important role in the
pathogenesis of diffuse large B cell lymphoma (DLBCL).
The present study was designed to investigate the clinical
and prognostic significance of survivin expression in nodal
DLBCL. We analyzed lymph node biopsy specimens
obtained from 56 patients with newly diagnosed nodal
DLBCL, treated with immunochemotherapy (R-CHOP).
The expression of survivin was analyzed using the standard
immunohistochemical method on formalin-fixed and rou-
tinely processed paraffin-embedded lymph node specimens
and evaluated semiquantitatively as a percentage of tumor
cells. Survivin immunoexpression ([45 % positive tumor
cells) was found in 22 (39.28 %) and observed as cyto-
plasmic staining in 15 patients, or mixed (cytoplasmic and
nuclear) staining in 7 patients. A significant difference in
survivin immunoexpression was noticed between the GCB
and the non-GCB subtypes of DLBCL (p = 0.031).
However, survivin immunoexpression had no significant
association with IPI, ‘‘bulky’’ disease, extranodal locali-
zation, hemoglobin, Ki-67 immunoexpression or other
clinicopathological parameters. A univariate analysis
showed that survivin positivity was an unfavorable factor
for therapy response and a predictor of shorter survival in
patients with DLBCL (p = 0.048 and p = 0.034, respec-
tively). Patients with survivin overexpression experienced
a relapse more often than patients without expression of
this apoptotic protein (27.3 vs. 11.8 %), but this difference
did not reach statistical significance (p = 0.131). The
results of this study showed that disregulation of survivin
expression had an important role in the determination of
the course of the disease in patients with nodal DLBCL
treated with R-CHOP. Therefore, survivin represents a
potential target for therapeutic intervention in DLBCL.
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Introduction
Diagnosed nodal diffuse large B cell lymphoma (DLBCL)
is an aggressive disease with variable clinical, histological,
immunophenotypic and cytogenetic features [1]. Although
the disease is very heterogeneous, initial treatment applied
to all patients with this type of lymphoma is almost always
the same [1], namely, in recent years, all newly diagnosed
patients with DLBCL have been treated with R-CHOP
protocol, which is the gold standard in treating this type of
lymphoma [2]. Although the addition of rituximab con-
tributed to the improvement of the therapeutic response and
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survival of patients with DLBCL, some patients do not
achieve a favorable therapeutic response or relapse after
successful treatment [2]. Thus, new prognostic tools for
identifying the patients who will not experience remission
following initial therapy and who need an additional or
more aggressive therapy are needed.
Apoptosis is a genetically regulated cell death mecha-
nism essential for the development and homeostasis of
multicellular organisms. It is regulated by two families of
proteins: the BCL2 family, comprising both pro- and anti-
apoptotic members [3], and the inhibitor of apoptosis
protein (IAP) family, consisting only of anti-apoptotic
molecules [4]. To date, eight members of the IAP family
have been identified in humans, among which survivin with
142 amino acid residues is the smallest. Expression of
survivin is consistently associated with the inhibition of
induced cell death in cell culture systems and in transgenic
animals as well, whereas survivin suppression triggers
caspase-dependent apoptosis both in vitro and in vivo [5].
Inactivation of survivin expression can restore TRAIL
sensitivity in resistant non-Hodgkin lymphoma B cells [6].
Previous studies have shown that deregulation of
apoptosis signaling cascade is an important factor in the
pathogenesis of lymphoma and that such deregulation may
be an important cause for chemotherapy resistance and a
poor prognosis in DLBCL [7–13]. Most of these studies
analyzed patients treated with conventional chemotherapy
(CHOP) [9–12], but there is only one study that analyzed
the prognostic significance of survivin in patients with
DLBCL treated with immunochemotherapy (ICH) [13].
Therefore, we analyzed whether immunoexpression of
anti-apoptotic protein survivin influences the therapy




We analyzed 56 patients with de novo nodal DLBCL
diagnosed from January 2004 to September 2008. The
diagnosis was established according to the criteria of the
World Health Organization classification [14]. A number
of clinical variables were particularly analyzed: age, gen-
der, clinical stage, ECOG, IPI, serum albumin, C-reactive
protein, ß2-microglobulin, LDH, hemoglobin concentration
and ‘‘bulky’’ disease. The staging of the disease was done
according to the Ann Arbor classification [15]. The Inter-
national Prognostic Index (IPI) score was determined, as
described previously [16]. The patients were subdivided
into the GBC and the non-GBC types according to the
model proposed by Hans et al. [17]. Patients with human
immunodeficiency virus positivity and patients with pri-
mary extranodal disease (CS IE or IIE) were excluded from
the study.
This study complied with all the provisions of the
Declaration of Helsinki and its current amendments and
was conducted in accordance with the Good Clinical
Practice Guidelines. The study was approved by the Insti-
tutional Ethical Committee.
Treatment
All patients were treated with immunochemotherapy: 51
patients received the R-CHOP regimen consisting of
cyclophosphamide, 750 mg/m2; doxorubicin, 50 mg/m2;
vincristine, 1.4 mg/m2 (up to a maximum dose of 2 mg) on
day 2; and prednisone, 60 mg, administered orally, on days
2–6. Rituximab was administrated at a dose of 375 mg/m2
on day 1. The treatment was repeated every 3 weeks. Five
patients received the R-EPOCH regimen consisting of rit-
uximab on day 1; etoposide, 50 mg/m on days 2–5;
doxorubicin, 10 mg/m on days 2–5; vincristine, 0.4 mg/m2
on days 2–5, administered as a continuous i.v. infusion;
prednisone, 60 mg/m2, administered orally on days 2–7;
and cyclophosphamide, 750 mg/m2 on day 7. The patients
in clinical stages II–IV were treated with six to eight cycles
of immunochemotherapy. The patients in the first clinical
stage were treated with three cycles of immunochemo-
therapy and ‘‘involved’’ field radiotherapy. The irradiation
therapy (30–40 Gy) was applied after immunochemother-
apy in the patients with ‘‘bulky’’ disease or with residual
disease. Treatment response was evaluated according to the
International Workshop Criteria [18].
Immunohistochemical studies
A tumor tissue was obtained from every patient by lymph
node biopsy, fixed in buffered formalin, at pH 7.4, and
embedded in paraffin. Then, 3-lm-thick paraffin-embedded
tissue samples were cut, deparaffinized in xylene and
rehydrated in water. The lymph node specimens were
analyzed by conventional light microscopy examination
and immunohistochemical analysis. The immunoexpres-
sion of survivin was assayed by means of the avidin/biotin/
peroxidase complex method (LSAB 2, DAKO or Ultravi-
sion LP Detection system, Labvision) using aminoethyl-
carbazole or DAB as a chromogen. A heat-induced epitope
retrieval method was used before the immunostaining,
namely sections were placed in 0.01 mmol/L citrate buffer
at pH 6.0 and heated twice in a microwave oven for 10 min
per cycle. The sections were stained with a survivin anti-
body (RB-9245-R7, Labvision, dilution 1:50). The anti-
body was incubated for half an hour at room temperature.
After the development of the chromogen, all slides were
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counterstained with hematoxylin. The control sections
were immunostained under identical conditions, substitut-
ing the primary antibody with a buffer solution. The tissue
of prostate carcinoma served as a positive control. The
expression of survivin was evaluated semiquantitatively as
a percentage of positive cells of all tumor cells. Only cells
three times larger than small lymphocytes were analyzed.
At least 500 cells were counted in each case. Lymph node
samples were evaluated at 1009 and 4009 magnifications
and independently analyzed by two observers (O.M., V.C.).
In case of disagreement, the observers reanalyzed the
staining results until they reached a consensus.
Statistical analysis
The statistical analysis was performed using SPSS version
15 software (SPSS Inc, Chicago Illinois, USA). The
determination of the optimum cutoff value for survivin
immunoexpression in prediction of overall survival was
performed by the receiver operating characteristic (ROC)
method, along with the determination of sensitivity and
specificity of all cutoff values. The chi-square test was used
to evaluate the differences in therapy response and survival
in relation to clinical and apoptotic parameters. Overall
survival (OS) was calculated as the time from establishing
the diagnosis to the date of death or last contact. Overall
survival was analyzed using the Kaplan–Meier method,
and the log-rank test was used to compare the difference in
the survival data. A multivariate analysis (Cox’s regression
analysis) was performed to examine the effect of presumed
prognostic factors on survival. All statistical tests were
two-sided, with p value B0.05.
Results
Patients’ characteristics
Clinical data were available for all patients, as summarized
in Table 1.
Immunohistochemical analysis
The percentage of positive tumor cells ranged from 1 to
95 % (the mean percentage of positive cells was 36/IQR
57/). According to the results of the ROC method, the
optimum cutoff value for survivin immunoexpression was
defined as[45 % positive tumor cells. Therefore, survivin
immunoexpression was found in 22 (39.28 %) patients and
observed as cytoplasmic staining in 15 patients, or as
mixed (cytoplasmic and nuclear) staining in 7 patients
(Fig. 1).
Correlation between survivin immunoexpression
and subtype and clinical parameters
We noticed a significant difference in survivin immuno-
expression between the GCB and the non-GCB subtype of
DLBCL (p = 0.031), namely survivin positivity was
noticed more often in the non-GCB than in the GCB sub-
type (Table 2). On the contrary, survivin immunoexpres-
sion was not in any significant correlation with the
Table 1 Clinical data and histological features of 56 DLBCL
patients
Age (years)
Median (IQR) 52.25 (16)
Range (19–87)
[60 11 (19.64 %)
Gender
Male/female 32 (57.14 %)/24 (42.86 %)
Stage
I 1 (1.78 %)
II 15 (26.78 %)
III 21 (37.5 %)
IV 19 (33.92 %)
ECOG
0 26 (46.43 %)
1 21 (37.50 %)
2 6 (10.71 %)
3 3 (5.35 %)
B symptoms 31 (55.35 %)
IPI
Low 23 (41.1 %)
Low/intermediate 16 (28.6 %)
High/intermediate 10 (17.9 %)
High 7 (12.5 %)
Bulky disease (C7 cm) 29 (51.8%)
(C10 cm) 12 (21.4 %)
Extranodal localization 19 (33.9 %
LDH ([460U/L) 34 (60.7 %)








Lymphocyte count (9109/L) 1.8 (1.2)
Range 0.3–11
Therapy
R-CHOP/R-EPOCH 51 (91.07 %)/5 (8.93 %)
GBC/non-GBC subtype 19 (51.4 %)/18 (48.6 %)
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analyzed clinical parameters: hemoglobin (p = 0.699), IPI
(p = 0.093), ‘‘bulky’’ disease (p = 0.313), extranodal
localization (0.397), lymphocyte count (0.327) and Ki-67
immunoexpression (p = 0.577).
Response to therapy
Therapy response was achieved in 45 (80.4 %) patients.
We noticed a significant difference in the likelihood of
achieving therapy response regarding survivin immunoex-
pression (p = 0.048). However, localization of survivin
expression (cytoplasmic vs. mixed) had no influence on
therapy response (p = 0.98) (Table 3). The relevance of
the clinical parameters for therapy response tested by the
chi-square test showed a significant difference in the
likelihood of achieving therapy response regarding
the following clinical parameters: ECOG (p = 0.003),
b-microglobulin (p = 0.03) and clinical stage (p = 0.002).
A relapse of the disease was noticed in 10 (17.85 %)
patients after a median follow-up of 40 months. There was
a difference in the relapse rate related to the immunoex-
pression of survivin, namely a relapse of the disease
appeared in 6 (27.3 %) survivin-positive patients and in 4
(11.1 %) survivin-negative patients, but this difference did
not reach statistical significance (p = 0.131).
Overall survival (OS)
The median follow-up period for OS of patients was
40 months (ranging from 2 to 72 months). At the time of
the final analysis, 35 (62.5 %) patients were alive and 21
(37.5 %) patients had died. The median survival period of
the whole group of analyzed patients was 39 months. A
univariate analysis showed that the following clinical
parameters were significantly associated with the overall
survival rate: ECOG (p \ 0.001), albumins (p = 0.007),
ß2-microglobulin (p = 0.012), extranodal localization
(p = 0.008), ‘‘bulky’’ disease (p = 0.011), clinical stage
(p = 0.039) and IPI (p \ 0.001). The immunoexpression
of survivin was also significantly associated with the
Fig. 1 Detection of survivin in biopsy specimens of primary nodal DLBCL—a survivin demonstrating cytoplasmic staining, b mixed staining
(original magnification 9400)
Table 2 Expression of survivin in the GCB and the non-GCB
subtype
Expression of survivin (%) GBC (%) Non-GBC (%) p
Survivin B 45 15 (65.2) 8 (34.8) 0.031
Survivin [ 45 4 (28.6) 10 (71.4)
Table 3 Therapy response and
survival according to expression
of survivin
Parameters Rate of therapy
response (%)






B45 31(91.17) 0.048 25(73.5) 0.034 4(11.84) 0.131
[45 14(63.63) 10(45.50) 6(27.3)
Survivin
Cytoplasmic 10(66.67) 0.98 7(46.6) 0.21 4(26.66) 0.33
Cytoplasmic ? nuclear 5(71.40) 2(42.85) 2(28.57)
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overall survival rate (p = 0.034) (Table 3), namely the
median survival period of survivin-positive patients was
not reached, while the median survival period of survivin-
negative patients was 26 months (Fig. 2). There was no
statistically significant difference in the survival of the
patients regarding localization of survivin expression
(cytoplasmic vs. mixed) (p = 0.21) (Fig. 3). A multivariate
analysis (Cox’s regression model) showed that only IPI is
an independent risk factor for the survival of the patients
with DLBCL.
Discussion
Previous studies have shown that deregulation of inhibitory
apoptotic proteins is an important factor in the pathogen-
esis of lymphoma and that such deregulation may be an
important cause for chemotherapy resistance and poor
prognosis in DLBCL [7–12]. The present study was con-
structed to clarify the meaning of survivin immunoex-
pression in patients with nodal DLBCL treated with
immunochemotherapy.
Survivin was first identified by Altieri from hybridiza-
tion screening of a human genomic library with the cDNA
of effector cell protease receptor/1(ERP/1) in 1997 [19].
The survivin gene located in 17q25 encodes multiple
alternately spliced mRNAs, which appear to be translated
into five different splice variants of proteins, the native,
full-length anti-apoptotic IAP-survivin, survivin-2B, sur-
vivin-DEx3, survivin-3B and survivin-2a [20]. It has been
demonstrated that some of these isoforms have subcellular
localization patterns that could be associated with unique
functional properties. Preliminary reports suggest that
survivin and survivin Ex3 have anti-apoptotic properties,
while survivin 2a attenuates the anti-apoptotic activity of
survivin. The function of survivin 2B has not been
described. Survivin inhibits apoptosis directly, by binding
to and inhibiting the activation of caspase [21], or indi-
rectly, by suppressing the activation of specific proapop-
totic factors [22], namely survivin binds and inhibits
caspase-9 and Smac/DIABLO function and also binds and
stabilizes other IAPs, for example, XIAP, promoting their
anti-apoptotic effect (9). In addition to its anti-apoptotic
function, survivin plays an essential role in cellular pro-
liferation as an essential component of the chromosome
passenger complex [23]. Survivin-DEx3 is also responsible
for modulating angiogenesis via several mechanisms
including cell invasion, migration and Rac/1 activation
[20].
Survivin is transiently expressed during embryonic
development, but barely detectable in normal, differenti-
ated adult tissue [19, 24]. In contrast, it has been found to
be expressed in a wide variety of solid tumors and malig-
nant hematological diseases [19, 25]. In some tumors, a
high level of survivin is a risk factor for resistance to
chemotherapy and a poor outcome [26, 27]. Overexpres-
sion of survivin correlates with reduced remission rates and
survival in pediatric patients with acute lymphoblastic
leukemia, adult patients with acute myeloid leukemia and
adult T cell leukemia, as well as diffuse large B cell
lymphoma [9, 28, 29].
Fig. 2 Kaplan–Meyer curve of survival of DLBCL patients accord-
ing to survivin immunoexpression
Fig. 3 Kaplan–Meyer curve of survival of DLBCL patients accord-
ing to localization of survivin immunoexpression
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In the present study, 39.28 % patients with DLBCL
were defined as survivin positive, and this figure is similar
to the results of previous studies [7–13]. Our results are
also in accordance with the results of most previous stud-
ies, which showed that a high level of survivin expression
correlates with a reduced remission rate and survival in
patients with DLBCL treated with chemotherapy. Since
limited data are available on patients treated with
immunochemotherapy [13], we showed that overexpres-
sion of survivin is in significant correlation with therapy
response and the survival of patients with nodal DLBCL
treated with immunochemotherapy. In other words, ritux-
imab cannot overcome a negative prognostic impact of
survivin overexpression in these patients. We also showed
an increased tendency in survivin-positive patients for a
relapse of the disease, although this difference was sig-
nificant only at p = 0.131 level.
Literature data about the prognostic significance of sub-
cellular localization of survivin (cytoplasmic or nuclear) are
contradictory [20], namely the prognostic significance of
cytoplasmic [9, 10, 12], as well as nuclear, positivity [11] has
been previously reported. However, it has recently been
shown that only cytoplasmic localization correlates with the
anti-apoptotic function of survivin and that the sensitivity of
cells to chemotherapeutic drugs is even increased when
survivin’s localization is restricted to the nucleus [30]. We
noticed cytoplasmic staining in most positive cases and
mixed (cytoplasmic and nuclear) staining in a smaller
number of patients, but a statistically significant difference
regarding the remission rate and OS between cytoplasmic
and mix (cytoplasmic and nuclear) staining was not found.
We noticed a significant difference in survivin expres-
sion between the GCB and the non-GCB type, which
means that survivin may contribute to a worse prognosis in
non-GCB patients. On the contrary, Watanuki-Miyauchi
et al. [31] showed that survivin-positive patients in both
subtypes tended to have a poor prognosis.
Interestingly, survivin overexpression was not in any
significant correlation with other, well-established clini-
copathological prognostic parameters in DLBCL: clinical
stage, IPI, ‘‘bulky’’ disease, proliferative activity and
extranodal localization. In addition, a multivariate analysis
showed that only IPI was an independent prognostic
parameter in our study group of patients with DLBCL.
In conclusion, disregulation of survivin in DLBCL is an
important step in the pathogenesis of DLBCL. Therefore,
survivin represents a very attractive target for new thera-
pies that could lead to further improvement in the treatment
for DLBCL. As at least five splice variants of survivin with
different functions have been described, further larger
studies are required in order to examine the expression of
all survivin isoforms and their prognostic significance in
DLBCL patients.
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